PortalPublikationenOne-week once-daily triple therapy with esomeprazole, moxifl...

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

Standard

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. / Miehlke, Stephan; Schneider-Brachert, Wulf; Kirsch, Christian; Morgner, Andrea; Madisch, Ahmed; Kuhlisch, Eberhard; Haferland, Christian; Bästlein, Elke; Jebens, Claus; Zekorn, Christian; Knoth, Holger; Stolte, Manfred; Lehn, Norbert.

in: HELICOBACTER, Jahrgang 13, Nr. 1, 02.2008, S. 69-74.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miehlke, S, Schneider-Brachert, W, Kirsch, C, Morgner, A, Madisch, A, Kuhlisch, E, Haferland, C, Bästlein, E, Jebens, C, Zekorn, C, Knoth, H, Stolte, M & Lehn, N 2008, 'One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin', HELICOBACTER, Jg. 13, Nr. 1, S. 69-74. https://doi.org/10.1111/j.1523-5378.2007.00588.x

APA

Miehlke, S., Schneider-Brachert, W., Kirsch, C., Morgner, A., Madisch, A., Kuhlisch, E., Haferland, C., Bästlein, E., Jebens, C., Zekorn, C., Knoth, H., Stolte, M., & Lehn, N. (2008). One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. HELICOBACTER, 13(1), 69-74. https://doi.org/10.1111/j.1523-5378.2007.00588.x

Vancouver

Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. HELICOBACTER. 2008 Feb;13(1):69-74. https://doi.org/10.1111/j.1523-5378.2007.00588.x

Bibtex

@article{5ae866099cbe486fb87fe73b384464ec,
title = "One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin",
abstract = "AIM: To investigate a 1-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of Helicobacter pylori infection.METHODS: Consecutive patients (n = 103) with at least one previous treatment failure and H. pylori infection resistant to both metronidazole and clarithromycin were treated with esomeprazole 40 mg, moxifloxacin 400 mg, and rifabutin 300 mg, given once daily for 7 days. Eradication was confirmed by histology and culture. CYP2C19 status was determined by polymerase chain reaction-restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were 77.7% (68.4-85.3) and 83.3% (74.4-90.2). Five patients discontinued prematurely (4.8%). Eradication was achieved in 93.1% of poor/intermediate metabolizers and in 78.8% of homozygous extensive metabolizers (p = .14). Eradication rates in patients with one, two, three, and four or more previous failures were 78.3%, 89.6%, 68.6%, and 88.9%, respectively (p = .21). The regimen was effective in seven of nine patients who previously failed quadruple therapy. Post-treatment resistance to moxifloxacin and rifabutin was detected in two (12.5%) and five (31%) patients after treatment failure.CONCLUSION: Once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin is a promising, safe, and convenient regimen for rescue therapy of H. pylori infection that may serve as a valuable alternative to quadruple therapy, particularly for patients with intolerance to amoxicillin.",
keywords = "Adult, Aged, Anti-Bacterial Agents, Aryl Hydrocarbon Hydroxylases, Aza Compounds, Clarithromycin, Cytochrome P-450 CYP2C19, Drug Resistance, Bacterial, Drug Therapy, Combination, Esomeprazole, Female, Fluoroquinolones, Gastric Mucosa, Helicobacter Infections, Helicobacter pylori, Humans, Male, Metronidazole, Middle Aged, Mixed Function Oxygenases, Polymorphism, Restriction Fragment Length, Prospective Studies, Quinolines, Rifabutin, Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't",
author = "Stephan Miehlke and Wulf Schneider-Brachert and Christian Kirsch and Andrea Morgner and Ahmed Madisch and Eberhard Kuhlisch and Christian Haferland and Elke B{\"a}stlein and Claus Jebens and Christian Zekorn and Holger Knoth and Manfred Stolte and Norbert Lehn",
year = "2008",
month = feb,
doi = "10.1111/j.1523-5378.2007.00588.x",
language = "English",
volume = "13",
pages = "69--74",
journal = "HELICOBACTER",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

AU - Miehlke, Stephan

AU - Schneider-Brachert, Wulf

AU - Kirsch, Christian

AU - Morgner, Andrea

AU - Madisch, Ahmed

AU - Kuhlisch, Eberhard

AU - Haferland, Christian

AU - Bästlein, Elke

AU - Jebens, Claus

AU - Zekorn, Christian

AU - Knoth, Holger

AU - Stolte, Manfred

AU - Lehn, Norbert

PY - 2008/2

Y1 - 2008/2

N2 - AIM: To investigate a 1-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of Helicobacter pylori infection.METHODS: Consecutive patients (n = 103) with at least one previous treatment failure and H. pylori infection resistant to both metronidazole and clarithromycin were treated with esomeprazole 40 mg, moxifloxacin 400 mg, and rifabutin 300 mg, given once daily for 7 days. Eradication was confirmed by histology and culture. CYP2C19 status was determined by polymerase chain reaction-restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were 77.7% (68.4-85.3) and 83.3% (74.4-90.2). Five patients discontinued prematurely (4.8%). Eradication was achieved in 93.1% of poor/intermediate metabolizers and in 78.8% of homozygous extensive metabolizers (p = .14). Eradication rates in patients with one, two, three, and four or more previous failures were 78.3%, 89.6%, 68.6%, and 88.9%, respectively (p = .21). The regimen was effective in seven of nine patients who previously failed quadruple therapy. Post-treatment resistance to moxifloxacin and rifabutin was detected in two (12.5%) and five (31%) patients after treatment failure.CONCLUSION: Once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin is a promising, safe, and convenient regimen for rescue therapy of H. pylori infection that may serve as a valuable alternative to quadruple therapy, particularly for patients with intolerance to amoxicillin.

AB - AIM: To investigate a 1-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of Helicobacter pylori infection.METHODS: Consecutive patients (n = 103) with at least one previous treatment failure and H. pylori infection resistant to both metronidazole and clarithromycin were treated with esomeprazole 40 mg, moxifloxacin 400 mg, and rifabutin 300 mg, given once daily for 7 days. Eradication was confirmed by histology and culture. CYP2C19 status was determined by polymerase chain reaction-restriction fragment length polymorphism.RESULTS: Intention-to-treat and per-protocol eradication rates were 77.7% (68.4-85.3) and 83.3% (74.4-90.2). Five patients discontinued prematurely (4.8%). Eradication was achieved in 93.1% of poor/intermediate metabolizers and in 78.8% of homozygous extensive metabolizers (p = .14). Eradication rates in patients with one, two, three, and four or more previous failures were 78.3%, 89.6%, 68.6%, and 88.9%, respectively (p = .21). The regimen was effective in seven of nine patients who previously failed quadruple therapy. Post-treatment resistance to moxifloxacin and rifabutin was detected in two (12.5%) and five (31%) patients after treatment failure.CONCLUSION: Once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin is a promising, safe, and convenient regimen for rescue therapy of H. pylori infection that may serve as a valuable alternative to quadruple therapy, particularly for patients with intolerance to amoxicillin.

KW - Adult

KW - Aged

KW - Anti-Bacterial Agents

KW - Aryl Hydrocarbon Hydroxylases

KW - Aza Compounds

KW - Clarithromycin

KW - Cytochrome P-450 CYP2C19

KW - Drug Resistance, Bacterial

KW - Drug Therapy, Combination

KW - Esomeprazole

KW - Female

KW - Fluoroquinolones

KW - Gastric Mucosa

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Male

KW - Metronidazole

KW - Middle Aged

KW - Mixed Function Oxygenases

KW - Polymorphism, Restriction Fragment Length

KW - Prospective Studies

KW - Quinolines

KW - Rifabutin

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/j.1523-5378.2007.00588.x

DO - 10.1111/j.1523-5378.2007.00588.x

M3 - SCORING: Journal article

C2 - 18205669

VL - 13

SP - 69

EP - 74

JO - HELICOBACTER

JF - HELICOBACTER

SN - 1083-4389

IS - 1

ER -